

For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older

DYANAVEL[®]XR[®]
(amphetamine) extended-release
tablets 5 mg•10 mg•15 mg•20 mg | oral suspension 2.5 mg/mL

You are invited to a Tris Pharma ADHD speaker program on DYANAVEL[®] XR (amphetamine) tablet

Please see Important Safety Information, including **BOXED WARNING** regarding **ABUSE, MISUSE, and ADDICTION**, below.

Title

Advancing ADHD Care: Long Duration, Less Supplementation

Presented by

Richard Young, Ph.D.

Medical Science Liaison, ADHD and CNS

Tris Pharma

Washington State University,
Pullman, WA

Location

Wild River Grille

17 S. Virginia St.

Reno, NV 89501

(inside the City Room)

Date & Time

Wednesday, October 1st, 2025

6:00 PM - 7:00 PM PST

To register, please contact your Tris Pharma Sales Representative or Alyssa Nishihira PA-C with The Nevada Academy of Physician Assistants (NAPA):

Please note that spouses or guests are not permitted to attend any part of the meeting or any of the meal functions unless they are appropriate healthcare professionals or office staff.

**Clint Ostenberg at (916) 862-0560 or costenberg@trispharma.com
Alyssa Nishihira, PA-C at (808) 346-5613 or nevadapa@hotmail.com**

INDICATION

DYANAVEL[®] XR (amphetamine) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE, MISUSE, AND ADDICTION

DYANAVEL XR has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DYANAVEL XR, can result in overdose and death. Before prescribing DYANAVEL XR, assess each patient's risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout treatment, reassess each patient's risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.

Please see additional Important Safety Information on page 2, and [Full Prescribing Information](#) for DYANAVEL XR, including **BOXED WARNING** regarding **ABUSE, MISUSE, and ADDICTION**, provided with this invitation.